Event Report: How is research in Ireland addressing the challenges of bowel cancer?

COLOSSUS, one of MErCuRIC’s “Related Projects” recently hosted a public event in Dublin and invited Coordinator Sandra Van Schaeybroeck to participate.

Professor Annette Byrne, Head of the Royal College of Surgeons Ireland (RSCI) Precision Cancer Medicine Group and Coordinator of the EC funded multi-million Euro Colorectal Cancer Research Programme COLOSSUS hosted and chaired the event at the RCSI on the 30th April 2019 in Dublin.   The meeting provided a fitting finale to Bowel Cancer Awareness Month throughout Europe.  She welcomed a packed audience and introduced three keynote speakers.

Coordinator of the MErCuRIC Project, Dr Sandra Van Schaeybroeck from Queen’s University, Belfast gave a comprehensive and enthralling lecture which summarised the aetiology of bowel cancer and provided current statistics on its prevalence in Europe and throughout the world.  She elaborated on current treatment options and new clinical approaches to the four stages of the disease.  The importance of early screening was emphasised given the lower survival rates from the more advanced stages, particularly Stage 4 where the cancer has spread to major organs such as the liver.  For example, 6 out of 10 colorectal cancer deaths could be prevented if all men and women over 50 years of age were screened routinely using the newest techniques.  Additionally, the removal of precancerous polyps reduced the probability of contracting colon cancer by 70%.

A major research challenge internationally has been to improve the survival outcome of stage 4 patients with genetic aberrations in KRAS/BRAF genes.  These patients are often resistant to historical chemotherapy options.  The MErCuRIC study, a major European collaboration between several countries, including the UK, Belgium, Spain, France, Italy, Czech Republic and Ireland, is investigating a unique combination therapy of immunotherapy and chemotherapy in order to treat patients with the above aberrations.  The project is now in Phase 2 and 82 patients have been recruited.

The next speaker, Dr Ian Miller (RCSI), delineated exciting new research work in their laboratories where there has been a particular focus on new developments in the search for more sensitive and specific biomarkers in order to predict particular types of colorectal cancer.  This lecture complemented the work of the previous speaker in stressing the importance of more precise identification of biomarkers which had the potential to pinpoint more effective therapies for the treatment and control of bowel cancer.

The final speaker, Dr Orla Casey (Cancer Trials Ireland), detailed the comprehensive programme of research which they had supported in recent years.  Additional to a large number of major clinical trials, there had been considerable effort expended on translational studies typified, for example, by the COLOSSUS study outlined by the Chairperson, Professor Annette Byrne, at the beginning of the session.  Biobank studies were continuing to prove of extreme value in making the most effective and efficient use of large datasets that were already available from patients.

The event, organised by Danielle Nicholson of Pintail Limited with assistance from Dr Alice O’Farrell (RCSI), was a major success and captivated a very attentive audience of health professionals and patients.  Dr Ed Goodall of Digestive Cancers Europe (DiCE) and the Northern Ireland Cancer Research Forum (NICRF) Patient Advocacy Representative commented, ‘The event did indeed provide a fitting finale to Bowel Cancer Awareness Month.  For Health Authorities the message was clear and explicit.  Instigate screening programmes for all male and females over 50 years of age and back them up with comprehensive awareness campaigns for potential patients.  Secondly, support the exciting research being conducted in our major universities prevent, diagnose and treat more effectively the various types and stages of colorectal cancer’.

Ed Goodall and Margaret Grayson catch up before the event

Sandra Van Schaeybroeck, Queen’s University Belfast at the speaker’s podium

Annette Byrne, RCSI and COLOSSUS Coordinator thanks speakers and attendees

MErCuRIC Coordinator joins forces for Bowel Cancer Awareness Month 2019

Prof. Sandra Van Schaeybroeck from Queen’s University Belfast, the Coordinator of the MErCuRIC project will join researchers involved in the COLOSSUS Project to facilitate a public forum in Dublin on 30 April 2019. In Ireland, April is “Bowel Cancer Awareness Month”. The event: “Colorectal Cancer- How is research in Ireland addressing the challenges?” will take place at the Royal College of Surgeons in Ireland (RCSI) from 18:30- 19:30. Prof Van Schaeybroeck’s talk is entitled “Current treatment options and clinical research approaches“. Sandra will provide a clinicians point of view and discuss the personalized medicine approach to treating colorectal, or bowel cancer. Other speakers include Prof Annette Byrne, Head of the RCSI Precision Cancer Medicine Group & Coordinator of the COLOSSUS Project, Dr Ian Miller, RCSI Precision Cancer Medicine Group and Dr Verena Murphy, Translational Research Leader at Cancer Trials Ireland.  

One of MErCuRIC’s Related Projects, COLOSSUS is an EU-funded Horizon 2020 project that aims to provide new and more effective ways to classify patients with a specific type of colorectal cancer (microsatellite stable RAS mutant metastatic colorectal cancer or MSS RAS mt mCRC) and to develop better treatments for them. The ultimate goal is to deliver a personalised medicine approach for patients with MSS RAS mt mCRC that is currently not available.

For more information, details about the event and to register, please visit Eventbrite.

MErCuRIC consortia meeting hosted by UNITO, Month 60

The MErCuRIC team of researchers assembled for the Month 60 plenary meeting on November 8th and 9th in Italy. On the 8th the group was met at the Candiolo Cancer Institute (IRCCS) and on the 9th at the Molecular Biotechnology Center of the University of Torino (UNITO).

After an overview and report on the project progress by Coordinator Sandra van Schaeybroeck, Queen’s University Belfast (QUB), Kylie O’Brien of Pintail Limited reminded partners of upcoming and remaining management reporting obligations and deadlines. Usharani Wahengbam, of the University of Oxford, discussed the Phase I trial of the MEK1/2 inhibitor Binimetinib with the cMET/ALK inhibitor Crizotinib in mCRC+. Then, Manuel Salto-Tellez shared the latest in digital pathology from QUB, followed by an update on the optimized Agilent panel and validation. Federica di Nicolantonia of UNITO also updated the team on the genomic analysis of tumour DNA (ctDNA) from MErCuRIC patients. As for the biorepository and sample distribution, Coordinator Sandra van Schaeybroeck led a discussion on the further analysis of the biosamples from MErCuRIC. BHSCT’s Ruth Boyd and Pintail’s Kylie O’Brien brought the group up-to-date with the dissemination work on MErCuRIC including the Public and Patient Involvement (PPI) in research activities. Vlad Popovici, Masarykova Univerzita presented the latest bioinformatics analysis and status of the data management system. There were also sessions for focussed discussions on the pre-clinical and translational advances and abstracts for future conferences and publications. The action points were reviewed and discussed before the end of the meeting.

Thanks to our hosts UNITO for the warm hospitality!

New Website Launched

Thank you very much for visiting our new website for the MErCuRIC project.

We’ll be updating the site over the next few weeks.